

Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement

Brian H. Eisner, David S. Goldfarb, Michelle A. Baum, Craig B. Langman, Gary C. Curhan,
Glenn M. Preminger, John C. Lieske, Gyan Pareek, Kay Thomas, Anna L. Zisman, Dimitri
Papagiannopoulos, Roger L. Sur

Brian H. Eisner— Massachusetts General Hospital, Boston, MA

David S. Goldfarb—NYU Langone Health and NYU School of Medicine
New York, NY

Michelle A. Baum—Division of Nephrology, Boston Children’s Hospital, Boston, MA

Craig B. Langman—Feinberg School of Medicine, Northwestern University, and Lurie
Children’s Hospital of Chicago, Chicago IL

Gary C. Curhan—Renal Division. Brigham and Women’s Hospital, Boston, MA

Glenn M. Preminger—Duke University Medical Center, Durham, NC

John C. Lieske—Mayo Clinic Division of Nephrology and Hypertension, Rochester, MN

Gyan Pareek—The Warren Alpert Medical School of Brown University
Providence, RI

Kay Thomas—Stone Unit, Guy’s and St Thomas’ NHS Foundation Trust, London and Kings
College, London

Anna L. Zisman—University of Chicago Pritzker School of Medicine, Chicago, IL

Dimitri Papagiannopoulos—UC San Diego Health, San Diego, CA

Roger L. Sur—UC San Diego Health, San Diego, CA

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Journal of Endourology

Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement (DOI: 10.1089/end.2019.0703)

Corresponding Author:

Brian H. Eisner

Dept of Urology, GRB 1102

Massachusetts General Hospital

55 Fruit Street

Boston, MA 02114

Ph: 617-726-3512

Fax: 617-726-6131

Email: beisner@partners.org

Article type: Review article

Running Head: Evaluation & management of cystine nephrolithiasis

Word Count: 3834

Tables: 0

Figures: 2

References: 45

Key words: cystinuria; calculi, genetic; nephrolithiasis, urolithiasis

ABSTRACT

Purpose: Cystinuria is a genetic disorder with both autosomal recessive or incompletely dominant inheritance. The disorder disrupts cystine and other dibasic amino acid transport in the proximal tubules of the kidney resulting in recurrent kidney stone formation.

Currently, there are no consensus guidelines on the evaluation and management of this disease. This manuscript represents the consensus of the author panel and will provide clinicians with a stepwise framework for the evaluation and clinical management of patients with cystinuria based on evidence in the existing literature.

Materials and Methods: A search of MEDLINE®/Pubmed® and the Cochrane database was performed using the key words “cystine nephrolithiasis,” “cystinuria,” “penicillamine, cystine,” and “tiopronin, cystine.” In total, as of May 2018 these searches yielded 2335 articles, which were then evaluated for their relevance to the topic of evaluation and management of cystinuria. Evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system.

Results: Twenty-five articles on the topic of cystinuria or cystine nephrolithiasis were deemed suitable for inclusion in this manuscript. The literature supports a logical evaluation process and step-wise treatment approach beginning with conservative measures: fluid intake and dietary modification. If stone formation recurs, proceed to pharmacotherapeutic options by first alkalinizing the urine and then using cystine-binding thiol drugs.

Conclusions: The proposed clinical pathways provide a framework for the efficient evaluation and treatment of patients with cystinuria that should improve overall outcomes of this rare, but highly recurrent form of nephrolithiasis.

INTRODUCTION

Cystinuria was first described in 1810 by William Hyde Wollaston, but erroneously called cystic oxide. Sir Archibald Garrod then correctly described it in the early 1900s. It is a genetic disorder that results from mutations in the genes *SLC3A1* and *SLC7A9*, which code for the 2 subunits of a transporter that mediate nearly complete reabsorption of cystine and other dibasic amino acids (ornithine, lysine, and arginine) in the renal proximal tubule and intestine. The disorder may be inherited in an autosomal recessive manner or as an autosomal dominant condition with variable expressivity.¹

Defects in reabsorption of cystine in the renal proximal tubular cells lead to excessive cystine in urine, prompting cystine precipitation in the distal renal tubule. Affected patients have a high propensity for cystine stone formation due to the relatively low solubility of cystine in urine, which may result in hundreds of stones per year as well as the development of chronic kidney disease (CKD) in severe cases.² Crystallization occurs when concentrations of cystine exceed 250 mg per liter of urine.

Apart from the formation of cystine stones, there are no other clinical manifestations secondary to the excessive loss of the 3 amino acids in the urine: ornithine, lysine, and arginine. Cystine stones comprise about 1% of all stones in adults and about 6% to 10% of stones in children. The estimated incidence of cystinuria is 1/7000 live births in the United States, though this estimate varies by geographic location and ethnicity.³ The average age at first presentation for cystinuria and kidney stones is 12 to 13 years of age. Recurrent episodes of nephrolithiasis may increase the subsequent development of hypertension, CKD, and end-stage kidney disease (ESKD).^{2,4}

Because cystinuria is a rare disease, many physicians, including nephrologists and urologists, may have limited experience caring for patients with this disorder. To address this gap, the International Cystinuria Foundation (www.cystinuria.org) recruited a panel of recognized experts who sought to perform a systematic review with the purpose of summarizing current clinical approach to management of cystinuria in adults and children.

MATERIALS AND METHODS

We performed a systematic review in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses statement). A search of MEDLINE®/Pubmed® and the Cochrane database was performed using the key words “cystine nephrolithiasis,” “cystinuria,” “penicillamine, cystine,” and “tiopronin, cystine.” In total, as of May 2018 these searches yielded 2335 articles, which were then evaluated for their relevance to the topic of evaluation and management of cystinuria according to PRISMA guidelines. A total of 2110 articles were excluded from screening (n=125 articles left); 100 potential articles were excluded from eligibility after reviewing abstracts (n=25 articles left). The remaining 25 full text articles were assessed and no further articles removed, leaving 25 eligible articles meeting criteria for inclusion in the recommendations for the treatment of patients with cystine nephrolithiasis (see Figure 1). Evidence was evaluated by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Case reports and case series were excluded. In addition to the above 25 articles, 14 extra basic science articles and non-cystinuria review articles in the field of stone prevention were also used as background for this manuscript (giving total 39 references).^{5,6}

Quality of the evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system: High = A, Moderate = B, Low = C, Very Low = D. When sufficient evidence was lacking for definitive conclusions, expert opinions were formulated based upon group consensus.

DIAGNOSIS

1. History

(Clinical principle). Clinicians should perform a detailed medical, dietary, and kidney stone history on a patient newly diagnosed with nephrolithiasis. Cystinuria should be considered in all patients if stone composition has never been confirmed and/or if a urine cystine screen has never been performed. Suspicion should be particularly high in children if a patient presents with one or more large stones or recurrent stones without a clinical diagnosis.

A detailed history includes the following: age of onset of stone disease; frequency of stone passage; stone number and size; stone-related procedure history; verification of cystine stone composition; family history of cystinuria or other stone disease; comorbid conditions that may affect the care or medical therapy of a patient with cystinuria (ie, chronic kidney disease); and lifestyle factors that may increase the risk of stone disease (ie, activities or occupations that may expose the patient to prolonged periods of dehydration or that may prohibit adequate intake of fluids). Dietary factors that increase the risk of stone formation for patients with cystinuria should also be elicited as in other stone formers, including low fluid intake and excessive dietary intake of sodium or non-dairy animal protein.⁷

2. Diagnosis

A diagnosis is confirmed if any of the following exist:

- a) Stone composition determined by x-ray crystallography or infrared spectroscopy.**
- b) Microscopy of spot urine demonstrating hexagonal crystals in the sediment.**
- c) Screening with the cyanide-nitroprusside qualitative test may be performed. When urine cystine excretion is greater than 75 mg/L, this spot test will turn the urine purple in color. Quantitative testing is then recommended, such as 1) 24-hour urine cystine measurement or 2) Random spot urinary cystine, ornithine, arginine, and lysine excretion normalized by creatinine excretion.**

Clinical recommendation: Because the dietary and pharmacologic treatment of patients with cystinuria is unique among stone-formers, confirmation of stone composition either by review of outside medical records or stone analysis is essential—as patients with cystinuria may rarely form non-cystine stones. If these data are not obtainable, a quantitative 24-hour urinary cystine level should be obtained; patients with heterozygous or homozygous mutations in the 2 genes known to cause cystinuria (*SLC3A1* and *SLC7A9*) will have a 24-hour cystine excretion greater than 80 mg/day. Microscopy using a spot

urine demonstrating hexagonal crystals is pathognomonic of cystinuria;⁸ however, quantitative 24-hour urinary testing should then be performed (**Standard; Evidence Strength: Expert opinion**).

EVALUATION

Clinicians should perform comprehensive metabolic evaluation including serum studies and 24-hour urine stone risk factors in all patients with newly diagnosed cystine nephrolithiasis or in recurrent cystine stone-formers who have not previously undergone metabolic evaluation. Twenty-four hour urine cystine levels, urinary cystine supersaturation, and capacity can be measured, but the optimal method of monitoring urine chemistry is uncertain (Standard; Evidence Strength: Expert opinion) Serum studies include serum electrolytes, bicarbonate, blood urea nitrogen, calcium, urate, and creatinine. One or two 24-hour urine samples should be collected while consuming a self-selected diet that can serve as a baseline to follow-up on the effects of dietary or pharmacologic intervention. Pertinent 24-hour stone risk factors include the following: total volume, urine pH, cystine, sodium, citrate, urate, creatinine (validates complete collection), and possibly urine urea nitrogen. Of note, patients with cystinuria may demonstrate urinary risk factors for formation of non-cystine stones as well.

RADIOLOGY

All patients should have radiologic imaging of the kidneys at the time of cystinuria diagnosis to assess the existing stone burden. Cystine stones are not very radiopaque and therefore plain films may fail to detect stones. The imaging at baseline could consist of an ultrasound or computed tomography without contrast. Besides establishing the magnitude of the initial stone burden, this study will serve as a baseline for later imaging. (**Standard; Evidence Strength: Expert opinion**)

Genetic Testing

At present, there is no clear indication for genetic testing since the phenotype of cystinuria does not appear to vary based upon the genotype, whether caused by 2 *SLC3A1* or *SLC7A9* mutations or one of each. Therapy also does not depend on the underlying genotype.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

However, as more is learned about the pathobiology associated with various genotypes and as the cost of genetic testing reduces, it is possible that genetic testing will be performed more frequently in the future.

TREATMENT

1. Daily fluid intake: clinicians should recommend a daily fluid intake to maintain a minimum of 3.0 liters/day/1.73m² of urine output spread throughout the day and evening in order to decrease urine cystine concentration and cystine crystallization.

Twenty-four hour urine cystine excretion can be used to modify this recommendation.

(Standard, Evidence Strength: Grade C) A single retrospective study demonstrated that a daily urine volume of 3.1 L may be associated with lower rates of cystine stone recurrence than a daily urine volume of 2.4 L.⁹ If 24-hour urine data are available, clinicians may use daily cystine excretion as a guide to modify this recommendation since urine cystine concentrations of >250-300 mg/L are associated with higher supersaturation and risk stone formation.^{9,10}

To decrease urine cystine concentration to less than 250 mg/L (approximately 1 mmol/L), oral fluid intake should be 2.5 to 4 L/day for adults, as tolerated, and scaled down appropriately for children to maintain the same relationship per 1.73m² body surface area as in adults. Desired urine output is at least >750 mL/24 hours in infants, >1000 mL/24 hours in young children up to 5 years of age, >1500 mL/24 hours up to 10 years of age, >2000 mL/24 hours in older children and adolescents, and >3,000 mL/24 hours in older adolescents and adults.

2. Dietary sodium intake: clinicians should recommend that dietary sodium intake be restricted to less than 2500 mg per day. (Standard, Evidence Strength: Grade C) Dietary sodium restriction has been shown to decrease urinary cystine excretion. Several studies have shown that cystine excretion increases linearly with urinary sodium excretion. Thus, urinary cystine decreases significantly on a low-sodium diet. These studies have demonstrated a benefit of sodium restriction (dietary < 2500 mg per day) for adults and children not treated with cystine binding thiol drugs, as well as in adult patients using

cystine-binding thiol drugs.¹¹⁻¹⁴ However, no study has been performed to demonstrate that sodium restriction actually prevents cystine stone formation.

3. Dietary animal protein intake: clinicians should recommend low intake of non-dairy animal protein for adults, and for patients to consider protein intake from non-animal sources. (Standard, Evidence Strength: Grade C) Foods of animal origin are rich in cystine and methionine, which is metabolized to cystine. Studies have shown that a high-protein diet with a large percentage of animal protein (70%) was associated with greater cystine excretion than a lower-protein diet composed of equal amounts animal and plant protein.¹⁵ A potential criticism of this study is that the experimental dietary parameters were extreme—under standard “real world” conditions, compliance with these diets may be challenging.

In addition, restriction of animal protein intake is associated with reduced net acid load requiring less urinary acid excretion. Potential benefits include a higher urine pH, greater cystine solubility, and reduction of the dose of alkali needed to achieve an increased urine pH (see below). In adults, these may be more easily accomplished on a diet restricted to less than 8 ounces of dietary animal protein per day. However, there have been no randomized, controlled studies examining the effects of dietary protein restriction or vegetarian diets on the prevention of cystine stone formation. In general, excessive dietary protein restriction is not recommended for children due to the requirement of protein intake for optimal growth; however, children should continue to achieve the Recommended Dietary Allowance for protein in their diets.¹⁵

4. Urinary alkalinization therapy should be prescribed to patients with recurrent cystine stones to achieve a urine pH goal of 7.0 to 7.5 (Standard, Evidence Strength: Grade C).

Cystine solubility is pH dependent and optimal urine pH in these patients is 7.0 to 7.5.^{10,16,17} Higher urine pH also improves the efficacy of cystine-binding thiol drugs *in vitro*.¹⁸ Potassium citrate or potassium bicarbonate is generally recommended as a first-line therapy for urinary alkalinization in patients with cystinuria due to its effect to raise urinary pH without increasing cystine excretion, unlike sodium citrate.¹⁹ It should also be noted that “over-alkalinization” (>7.5) has the potential to induce the formation of calcium

phosphate stones; therefore, the composition of new stones should be determined in patients taking alkali rather than assuming it to be cystine. Sodium bicarbonate is sometimes associated with fewer gastrointestinal adverse effects than potassium citrate. Alkalinization with sodium bicarbonate or sodium citrate should be considered a second-line therapy since increased urinary sodium increases urinary cystine excretion.^{11-14,19} The recommended target urine pH is 7.0 to 7.5.

5. Pharmacotherapy with cystine-binding thiol drugs (CBTD): clinicians should offer CBTD to patients with frequent, recurrent cystine stones who have failed therapy with fluids, diet, and alkalinization. Use of capacity assay (Litholink, Chicago, IL; www.litholink.com) is recommended given unreliability of cystine measurements once CBTD are introduced—with the goal of treatment being “positive” capacity ideally > 50mg/L (Standard, Evidence Strength: Grade C). The 2 most commonly used and studied cystine-binding thiol drugs are alpha-mercaptopropionylglycine (tiopronin) and d-penicillamine. This class of drugs, each containing a thiol group, accomplishes disulfide exchange with cystine. The result is the formation of a soluble drug-cystine complex. Both medications reduce free urinary cystine levels and decrease the risk of recurrence of cystine stones in retrospective, non-randomized studies.²⁰⁻²⁴ However, these drugs do not reduce cystine excretion.^{19, 25} Few studies have directly compared d-penicillamine and tiopronin, but the single largest study demonstrated equal effectiveness of the 2 drugs. Of note, tiopronin had fewer adverse effects.²⁴ Citing this study, the 2014 American Urological Association (AUA) guideline for the medical management of kidney stones recommended tiopronin as first-line pharmacotherapy for patients with cystinuria for whom alkalinization and high fluid intake were not sufficient to reduce further stone formation.³ Oral vitamin B6 (50 mg daily) should be given to prevent possible B6 (pyridoxine) deficiency that can result from penicillamine chelation of pyridoxine.

In July 2019, FDA approved a new preparation of tiopronin called Thiola EC, for “enteric coated.” Our experience with this preparation is quite limited at the time of this publication. The tablets reduce pill burden as they are 300 mg, instead of the original 100 mg tablet. The enteric coating leads to a more sustained release, which may have a clinical benefit, which has not yet been demonstrated. In addition, this preparation does not

require careful spacing with respect to meals, unlike the original Thiola preparation, and does prohibit administration of the drug during pregnancy.

Tiopronin dosing for adults usually begins at 600 mg to 900 mg daily divided 3 times a day. In children, the FDA-approved tiopronin dosing should begin at 15 mg/kg/day and is only indicated for pediatric patients weighing 20 kg or more. D-penicillamine is dosed at 500 mg to 1500 mg per day divided in 2 or 3 doses. For clinicians who are unable to obtain cystine concentration, a reasonable therapy target goal is 1 mg tiopronin for every 1 mg cystine excretion per 24 hours.

Many clinicians who treat cystinuria suggest that ideal dosing should reduce cystine concentration to <250 mg/L to 350mg/L. However, optimal dosing is not as straightforward. The measurement of cystine concentration is confounded by the presence of thiol-binding drugs, which render the measurement of cystine levels inaccurate. Specifically, assays cannot distinguish cystine from soluble cysteine-thiol drug complex. For example, with colorimetric assays, cystine concentration cannot be reliably measured and may detect free cystine or cysteine-thiol drug complex.⁷ A high-performance liquid chromatographic (HPLC) method may be able to distinguish the two, but often sample preparation will disrupt the cysteine-thiol drug complex and will impact measurement and reported results.²⁶ All of these parameters may impact the report of cystine excretion and cystine supersaturation. An *in vitro* based study suggests that liquid chromatography tandem mass spectrometry can differentiate cystine from cysteine-tiopronin complex, though this is not clinically available.²⁷ Hence, it has been difficult to determine the best values to interpret in follow-up 24-hour urines in patients with cystinuria currently treated with thiol drugs.

A proprietary solid phase assay is fortunately available to directly, accurately measure cystine supersaturation in presence or absence of CBTD.²⁸ Available through Litholink (Chicago, IL; www.litholink.com), the assay coins the measurement as “capacity.” A known amount of solid cystine is added to patient urine and incubated. The amount of solid phase is then measured. In an undersaturated urine, the solid phase recovered is less than originally added since some of it dissolves in the undersaturated urine. This is reported as

a *positive capacity*. In a saturated urine, the solid phase recovered is greater than originally added since the supersaturated urine adds mass to the original solid cystine. This is reported as a *negative capacity*.

In a small study of 7 patients, patients served as their own controls and were tested both off CBTD and then on CBTD, and capacity improved while on CBTD.²⁹ A more recent and larger prospective cohort study supports the clinical utility of a capacity tool amongst mixed population of CBTD and conservative treatment. They sought to correlate capacity to stone formation activity. They showed capacity ranged from -841 to +307 and more importantly demonstrated inverse relation of capacity to stone activity: stone quiescence versus stone activity, mean +/-SD 48+/-107 mg/L versus -38 +/- 163mg/L, $P<0.001$, respectively.³⁰ Therefore a capacity of >50 mg/L has been commonly accepted as a target threshold for clinicians.

Pharmacotherapy with captopril, an angiotensin converting enzyme (ACE) inhibitor containing a thiol group, has not been reproducibly demonstrated to decrease cystine stone formation in adults. At a maximum dose of 150 mg per day, urinary excretion of cystine does not achieve a sufficient number of millimoles of thiol to have an appreciable effect on cystine solubility. Therefore, captopril is not recommended for the routine treatment of adult patients with cystinuria.³¹⁻³³ Nevertheless, captopril (0.3 mg/kg/day to 1.5 mg/kg/day) may be an appropriate therapeutic option to treat hypertension in cystinuric patients or in children who cannot use oral tiopronin due to its capsule size.

FOLLOW UP CARE

1. Obtain a single 24-hour urine within 1 to 2 months of the initiation of dietary modification or pharmacotherapy. After initial follow up, periodic 24-hour urine studies should be performed to measure changes produced by the prescribed dietary or pharmacologic therapy, with a goal of urinary cystine concentration <250 mg/L and pH >7.0. The frequency of testing may be reduced to semi-annually or annually when metabolic activity has stabilized. (Standard; Evidence Strength: Expert opinion) Several observational studies have demonstrated that among patients with calcium-based stones, urinary compositional changes are associated with a decrease in recurrent stone episodes;

we extrapolate these observations to patients with cystinuria.³⁴⁻³⁷ Moreover, previous studies suggest that close follow-up of patients with cystinuria is essential to encourage compliance with medical therapy.³⁸ Patient compliance as well as the ongoing evaluation of other non-cystine urinary stone risk factors should also be evaluated as part of this follow-up regimen.

2. For patients prescribed CBTs, comprehensive metabolic panel and spot measurement of urine protein/creatinine ratio should be obtained at baseline (within 3 to 6 months of initiating treatment, and every 6 to 12 months yearly thereafter). Serum B6 levels should be monitored annually for penicillamine use (Standard; Evidence Strength: Expert opinion) Side effects of penicillamine can be monitored by routine laboratory testing for anemia, neutropenia, thrombocytopenia, liver function, and urine albumin excretion and for tiopronin, urine albumin excretion.²⁴ The monitoring of complete blood counts and liver function tests are no longer required according to the FDA-approved prescribing information for Thiola EC. The most common histologic finding causing proteinuria is membranous nephropathy. Other potential side effects, which should be screened by a review of systems, include gastrointestinal symptoms (taste disturbance, nausea, emesis, diarrhea, abdominal pain), dermatological symptoms, hyperelasticity (rash, urticaria), photosensitivity, hair loss, and hypersensitivity reactions. Anecdotal evidence suggests that adverse events can be rechallenged after their resolution at the clinician's discretion. Patient with cystinuria are at risk for CKD, therefore serum creatinine should be measured at least yearly. CBTs should be discontinued if they are associated with significant proteinuria.

3. Clinicians should obtain periodic imaging with ultrasonography or low-dose computerized tomography (CT) to assess for stone recurrence, stone burden, and stone growth. (Standard; Evidence Strength: Expert opinion) Low radiation non-contrast CT is nevertheless the gold standard imaging modality for acute urolithiasis and has the highest sensitivity and specificity for stone disease. Renal ultrasound may suffice for screening purposes and avoids exposure to ionizing radiation, although sensitivity is poor for smaller stones. Recently, digital tomosynthesis has been proposed as another option to non-contrast CT with lower cost and decreased ionizing radiation.³⁹ Imaging frequency can be

tailored to patients' symptoms or frequency of stone events. For patients who are stable without symptoms or recurrent stone formation, a minimum of 12-month imaging interval is recommended. For all stone-formers, the AUA guideline recommends a 1-year imaging interval for asymptomatic patients, but frequency can be decreased over time provided no stone recurrence.³⁴

4. Siblings of people with cystinuria should undergo screening for cystinuria. (Standard; Evidence Strength: Expert opinion). At present, routine genotyping of people with cystinuria is not recommended. Screening of siblings of a newly identified patient with cystinuria can be performed with a single 24-hour urine collection to measure urine cystine excretion or with a random urine screen for amino acids ratioed to urine creatinine. Finding asymptomatic cystinuria >80 mg/24 hours should lead to performance of a renal ultrasound.

Future directions

Recently, there is possibility of new drugs being developed for the treatment of cystinuria. A series of diamines, which mimic cystine and interfere with its crystallization have shown efficacy *in vitro* and in a knock-out mouse model.⁴⁰⁻⁴² The effect of these molecules is attributed to steric hindrance, where side chains prevent additional molecules of cystine from being added to crystals. No studies of these drugs in humans with cystinuria have been performed as of yet.

Another promising compound is alpha-lipoic acid, which has a significant inhibitory effect on cystine stone formation *in vitro* and in the knock-out mouse model.⁴³ Currently alpha-lipoic acid is being tested in people with cystinuria in a trial.⁴⁴

Ultimately, cystinuria could be amenable to correction by genetic therapy. Targeting a functional cystine transporter to the proximal tubule is particularly complex. A recent proposal, not yet tested in an animal model, takes advantage of the ability of certain aminoglycosides to bridge nonsense mutations. These drugs are concentrated in the nephron and could allow a more functional cystine transporter to be translated in the appropriate location.⁴⁵

CONCLUSION

Based on the cited literature, clinical principles, and expert recommendations, a stepwise algorithm for the evaluation and medical management of patients with cystinuria and urolithiasis is provided (Figure 2). Briefly, the steps are as follows: a high index of suspicion is necessary in patients who present early in life, along with confirmatory stone analysis and 24-hour urinary analysis. Following a cystine diagnosis, lifestyle and dietary recommendations (maintaining 3 L urine output/day and moderate dietary sodium and animal protein) are suggested. If conservative measures fail to reduce the urinary cystine concentration <250 mg/L, the next step is initiating alkali therapy with potassium citrate 2 or 3 times per day to achieve 24-hour urinary pH of 7.0 to 7.5.

If these measures fail to reduce the urinary cystine concentration <250mg/L or cystine stones recur, consider initiation of therapy with CBTD. Urine studies should be repeated and thiol doses titrated as necessary to create positive capacity (Litholink, Chicago, IL) ideally >50 mg/L. Recurrent stone formation may also indicate that higher doses are appropriate. Lastly, lifelong follow-up with both serial 24-hour urines and routine imaging are necessary to prevent stone recurrence.

Acknowledgements:

We would like to thank Gayle Sweeney of the International Cystinuria Foundation for her support of this initiative. Additionally, we would want to extend our gratitude to our editor, Jessica Bogdany, who has spent countless hours managing the editing of this manuscript.

We sincerely hope the collaborative work will "move the needle" of care for those suffering from cystinuria.

Author Disclosure Statement:

Brian H. Eisner is a consultant for Allena Pharmaceuticals and Retrophin and is a patent holder and owner of Dr. Arnie's, Inc. David S. Goldfarb is a consultant and has received honoraria from Retrophin, and is a patent holder and owner of Dr. Arnie's, Inc. Michelle A. Baum provides medical advisory to Retrophin. No competing financial interests exist for

Craig B. Langman. Gary C. Curhan is a consultant for Allena Pharmaceuticals, Shire, RenalGuard Solutions, and Akuous. He has also received grant funding from SHOEBOX Audiometry and personal fees from UpToDate. Glenn M. Preminger is a consultant for Retrophin. No competing financial interests exist for Gyan Pareek or Kay Thomas. John C. Lieske has received grant funding from Retrophin. Anna L. Zisman is a consultant for Retrophin. No competing financial interests exist for Dimitri Papagiannopoulos. Roger L. Sur is a consultant and speaker for Boston Scientific; a speaker for Cook Medical and Karl Storz; and a speaker and advisory board member for Retrophin. He is also the Chief Medical Officer for Kalera Medical, Inc and Pacific Litho San Diego LLC.

REFERENCES

1. Fattah H, Hambaroush Y, Goldfarb DS. Cystine nephrolithiasis. *Transl Androl Urol* 2014; 3:228-233.
2. Prot-Bertoye C, Lebbah S, Daudon M, et al. CKD and its risk factors among patients with cystinuria. *Clin J Am Soc Nephrol* 2015; 10:842-851.
3. Rogers A, Kalakish S, Desai RA, Assimos DG. Management of cystinuria. *Urol Clin North Am* 2007; 34:347-362.
4. Edvardsson VO, Goldfarb DS, Lieske JC, et al. Hereditary causes of kidney stones and chronic kidney disease. *Pediatr Nephrol* 2013; 28:1923–1942.
5. Shekelle PG, Woolf SH, Eccles M, et al. Developing clinical guidelines. *West J Med* 1999; 170:348-351.
6. Lavergne V, Nolin TD, Hoffman RS, et al. The EXTRIP (EXtracorporeal TReatments In Poisoning) workgroup: guideline methodology. *Clin Toxicol (Phila)* 2012;50: 403-413.
7. Goldfarb DS, Coe FL, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. *Kidney Int* 2006; 69:1041–1047.
8. Lewis HB. The occurrence of cystinuria in healthy young men and women. *Ann Intern Med* 1932; 6:183-192.
9. Barbey F, Joly D, Rieu P, et al. Medical treatment of cystinuria: Critical reappraisal of long-term results. *J Urol* 2000; 163:1419-1423.
10. Nakagawa Y, Asplin JR, Goldfarb DS, et al. Clinical use of cystine supersaturation measurements. *J Urol* 2000; 164(5):1481-1485.
11. Jaeger P, Portmann L, Saunders A, et al. Anticystinuric effects of glutamine and of dietary sodium restriction. *N Engl J Med* 1986; 315:1120-1123.

12. Lindell A, Denneberg T, Edholm E, et al. The effect of sodium intake on cystinuria with and without tiopronin treatment. *Nephron* 1995;71:407-415.
13. Norman RW, Manette WA. Dietary restriction of sodium as a means of reducing urinary cystine. *J Urol* 1990; 143:1193-1195.
14. Rodriguez LM, Santos F, Malaga S, et al. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. *Nephron* 1995; 71:416-418.
15. Rodman JS, Blackburn P, Williams JJ, et al. The effect of dietary protein on cystine excretion in patients with cystinuria. *Clin Nephrol* 1984; 22:273-278.
16. Dent CE, Senior B. Studies on the treatment of cystinuria. *Br J Urol* 1955; 27:317-332.
17. Pak CY, Fuller CJ. Assessment of cystine solubility in urine and of heterogeneous nucleation. *J Urol* 1983; 129:1066-1070.
18. Asplin DM, Asplin JR. The interaction of thiol drugs and urine pH in the treatment of cystinuria. *J Urol* 2013; 189:2147-2151.
19. Fjellstedt E, Denneberg T, Jeppsson JO, et al. A comparison of the effects of potassium citrate and sodium bicarbonate in the alkalinization of urine in homozygous cystinuria. *Urol Res* 2001; 29:295-302.
20. Remien A, Kallistratos G, Burchardt P. Treatment of cystinuria with thiola (alpha-mercaptopropionyl glycine). *Eur Urol* 1975; 1:227-228.
21. Halperin EC, Thier SO, Rosenberg LE. The use of D-penicillamine in cystinuria: efficacy and untoward reactions. *Yale J Biol Med* 1981; 54:439-446.
22. Lindell A, Denneberg T, Hellgren E, et al. Clinical course and cystine stone formation during tiopronin treatment. *Urol Res* 1995; 23:111-117.
23. Pareek G, Steele TH, Nakada SY. Urological intervention in patients with cystinuria is decreased with medical compliance. *J Urol* 2005; 174:2250-2252, discussion 2252.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

24. Pak CY, Fuller C, Sakhaee K, et al. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. *J Urol* 1986; 136:1003-1008.
25. Johansen K, Gammelgard PA, Jorgensen FS. Treatment of cystinuria with alpha-mercaptopropionylglycine. *Scand J Urol Nephrol* 1980; 14:189-192.
26. Campanella L, Crescentini G, Avino P. Simultaneous determination of cysteine, cystine and 18 other amino acids in various matrices by high-performance liquid chromatography. *J Chromatogr* 1999; 833:137-145.
27. Giesen CD, Chirackal RS, Brady C, Voskoboev N, et al. Interference of tiopronin with urine cystine measurement is assay-dependent. Abstract presented at: Kidney Week with American Society of Nephrology; November 2, 2017; New Orleans, Louisiana.
28. Coe FL, Clark C, Parks JH, et al. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. *J Urol* 2001; 16:688-693.
29. Dolin DJ, Asplin JR, Grasso M, et al. Effect of cystine-binding thiol drugs on urinary cystine capacity in patients with cystinuria. *J Endourol* 2005; 19:429-432.
30. Friedlander JI, Antonelli, JA, Canvasser N, et al. Do urinary cystine parameters predict clinical stone activity? *J Urol* 2018; 199:495-499.
31. Cohen TD, Strem SB, Hall P. Clinical effect of captopril on the formation and growth of cystine calculi. *J Urol* 1995; 154:164-166.
32. Coulthard M, Richardson J, Fleetwood A. Captopril is not clinically useful in reducing the cystine load in cystinuria or cystinosis. *Pediatr Nephrol* 1991; 5:98.
33. Sloand JA, Izzo JL, Jr. Captopril reduces urinary cystine excretion in cystinuria. *Arch Intern Med* 1987; 147:1409-1412.
34. Pearle MS, Goldfarb DS, Assimos DG, et al. Medical management of kidney stones: AUA guideline. *J Urol* 2014; 192:316-324.

This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.

Journal of Endourology
Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement (DOI: 10.1089/end.2019.0703)

35. Robinson MR, Leita VA, Haleblan GE, et al. Impact of long-term potassium citrate therapy on urinary profiles and recurrent stone formation. *J Urol* 2009; 181:1145-1150.
36. Pak CY, Heller HJ, Pearle MS, et al. Prevention of stone formation and bone loss in absorptive hypercalciuria by combined dietary and pharmacological interventions. *J Urol* 2003; 169:465-469.
37. Borghi L, Schianchi T, Meschi T, et al. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. *N Engl J Med* 2002; 346:77-84.
38. Pietrow PK, Auge BK, Weizer AZ, et al. Durability of the medical management of cystinuria. *J Urology* 2003; 169:68-70.
39. Cabrera FJ, Kaplan AG, Youssef RF, et al. Digital tomosynthesis: a viable alternative to noncontrast computed tomography for the follow-up of nephrolithiasis? *J Endourol* 2016; 30:366-370.
40. Rimer JD, An Z, Zhu Z, et al. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. *Science* 2010; 330:337-341.
41. Yang Y, Albanyan H, Lee S, et al. Design, synthesis, and evaluation of l-cystine diamides as l-cystine crystallization inhibitors for cystinuria. *Bioorg Med Chem Lett* 2018; 28:1303-1308.
42. Hu L, Yang Y, Aloysius H, et al. l-Cystine diamides as l-cystine crystallization inhibitors for cystinuria. *J Med Chem* 2016; 59:7293-7298.
43. Zee T, Bose N, Zee J, et al. α -Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria. *Nat Med* 2017; 23:288-290.

44. Lipoic acid supplement for cystine stone (ALA). ClinicalTrials.gov.
<https://clinicaltrials.gov/ct2/show/NCT02910531>. Last updated April 17, 2019. Accessed January 13, 2020.
45. Tokhmafshan F, Dickinson K, Akpa MM, et al. A no-nonsense approach to hereditary kidney disease. *Pediatr Nephrol* 2019; doi: 10.1007/s00467-019-04394-5.

Abbreviations Used

ACE= angiotensin converting enzyme.

AUA= American Urological Association.

CBTD= cystine-binding thiol drugs.

CKD= chronic kidney disease.

CT= computerized tomography.

ESKD= end-stage kidney disease.

GRADE= Grading of Recommendations Assessment, Development, and Evaluation.

HPLC= high-performance liquid chromatographic.

Note: there are no figure legends, so below are the Figure titles.

Journal of Endourology
Evaluation and medical management of patients with cystine nephrolithiasis: a consensus statement (DOI: 10.1089/end.2019.0703)
This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.





Figure 1: Article search methodology

Figure 1. Article search methodology

Figure 2



*Pertinent 24-hour stone risk factors include the following: total volume, urine pH, cystine, sodium, citrate, urate, creatinine (validates complete collection), and possibly urine urea nitrogen.

Figure 2: Recommended clinical algorithm